

Technology Appraisal Committee A Interests Register

Topic: Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment [ID3753]

Publication Date: 12 June 2026

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Becky Pennington	TAC Committee Member	Indirect - Financial	Becky has an ongoing methods research project with Pfizer on carers' HRQoL, paid to my employer UoS.	15/01/2026	It was agreed that Becky's declaration would not prevent her from participating in discussions on this appraisal.
Gemma Eminowicz	Clinical Expert	Direct Financial	<p>Consulting and advisory board fees from MSD, Eisai, Regeneron and GSK:</p> <p>GSK Advisory boards – April and June 2024</p> <p>Consultancy contract with MSD started October 2023 working on real world endometrial cancer data and PRO reporting.</p> <p>MSD advisory board July 2024 on first line advanced endometrial cancer treatment and role of pembrolizumab/dostarlimab</p>	11/09/2025	It was agreed that Dr Eminowicz's declaration would not prevent her from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>Regeneron advisory board Jan 2025 on cemiplimab in second line metastatic cervical cancer</p> <p>Consultancy contract with Eisai started focusing on information leaflet production etc</p> <p>Payments also received for delivery of educational sessions/symposia/webinar – MSD, GSK and Eisai</p>		
Lisa Barraclough	Clinical Expert	Direct – Financial	Received direct payment from Genmab for attending the above mentioned 'round table' meeting in May 2025.	12/09/2025	It was agreed that Dr Barraclough's declaration would not prevent her from providing expert advice to the committee.